Template:PDB Gallery/5602

• 1jnk: THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP

  1jnk: THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP

• 1pmn: Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor

  1pmn: Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor

• 1pmq: The structure of JNK3 in complex with an imidazole-pyrimidine inhibitor

  1pmq: The structure of JNK3 in complex with an imidazole-pyrimidine inhibitor

• 1pmu: The crystal structure of JNK3 in complex with a phenantroline inhibitor

  1pmu: The crystal structure of JNK3 in complex with a phenantroline inhibitor

• 1pmv: The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor

  1pmv: The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor

• 1ukh: Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125

  1ukh: Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125

• 1uki: Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125

  1uki: Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125

• 2b1p: inhibitor complex of JNK3

  2b1p: inhibitor complex of JNK3

• 2exc: Inhibitor complex of JNK3

  2exc: Inhibitor complex of JNK3

• 2g01: Pyrazoloquinolones as Novel, Selective JNK1 inhibitors

  2g01: Pyrazoloquinolones as Novel, Selective JNK1 inhibitors

• 2gmx: Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity

  2gmx: Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity

• 2h96: Discovery of Potent, Highly Selective, and Orally Bioavailable Pyridine Carboxamide C-jun NH2-terminal Kinase Inhibitors

  2h96: Discovery of Potent, Highly Selective, and Orally Bioavailable Pyridine Carboxamide C-jun NH2-terminal Kinase Inhibitors

• 2no3: Novel 4-anilinopyrimidines as potent JNK1 Inhibitors

  2no3: Novel 4-anilinopyrimidines as potent JNK1 Inhibitors

• 2o0u: Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide

  2o0u: Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide

• 2o2u: Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide

  2o2u: Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide

• 2ok1: Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide

  2ok1: Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide